Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stavudine and Didanosine in HIV-Infected Children
NCT00000851Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of stavudine and didanosine in human immunodeficiency virus infection (HIV) (3 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Safety evaluation at 48 weeks and Pharmacokinetic disposition. Status: completed.
02
Drugs
stavudinedidanosine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00000851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00000851.